Histiocytosis
6 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Narrower: Erdheim-Chester Disease 2
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| FOLFIRI + FOLFOX6/FOLFOX7 + S241656 + PANITUMUMAB + Cetuximab for histiocytosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lenalidomide for erdheim-chester disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S241656 for histiocytosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S241656 + PEMBROLIZUMAB for histiocytosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S241656 + Trametinib for histiocytosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trametinib + DABRAFENIB for erdheim-chester disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.